INTRODUCTION {#s1}
============

Non-small cell lung cancer (NSCLC) accounts for more than 85% of total lung cancer cases \[[@R1]\], and 5-year patient survival remains low at only 15.9% \[[@R1]\]. The most common NSCLC histological phenotypes are lung adenocarcinoma (LADC, ∼50% of patients) and lung squamous cell carcinoma (LSCC, ∼40% of patients) \[[@R1]\]. LADC cells commonly exhibit abnormal gene expression patterns and large numbers of gene mutations \[[@R2]\], and are characterized by specific biomarkers\[[@R3]--[@R7]\] and prognostic factors \[[@R8]--[@R10]\] that can be used to guide clinical diagnosis and treatment. LSCC cells also exhibit complex genomic alterations, including numerous gene mutations and copy number alterations \[[@R11]\], and are associated with particular biomarkers \[[@R12]--[@R14]\] and prognostic factors \[[@R15]--[@R17]\].

Accurate diagnosis of the LADC and LSCC cancer types has important significance for lung patient clinical treatment. While biomarkers that differentiate LADC from LSCC have been reported previously \[[@R18]--[@R21]\], additional markers would help enhance diagnostic accuracy for these intractable malignant cancers. The present study identified differentially expressed genes (DEGs) between LADC and LSCC samples using comprehensive bioinformatics analyses. We identified eight potential biomarkers for discriminating LADC and LSCC, and assessed their prognostic values.

RESULTS {#s2}
=======

Study design {#s2_1}
------------

We imported four Gene Expression Omnibus (GEO) datasets (GSE28571, GSE37745, GSE43580, and GSE50081) into the Gene-Cloud of Biotechnology Information (GCBI) bioinformatics analysis platform (Figure [1](#F1){ref-type="fig"}). We extracted LADC and LSCC gene expression information from these datasets and identified DEGs between the two cancer types. From the top 10 down- or upregulated DEGs, we identified eight as potential biomarkers for discriminating LADC and LSCC. We assessed the prognostic values of these potential biomarkers using the survival analysis tools, PrognoScan and Kaplan-Meier Plotter.

![Study design diagram\
LADC: lung adenocarcinoma; LSCC: squamous cell carcinoma; DEGs: differentially expressed genes; GCBI: Gene-Cloud of Biotechnology Information.](oncotarget-08-71759-g001){#F1}

DEGs in LADC and LSCC {#s2_2}
---------------------

Using GCBI, we identified 243, 210, 118, and 101 potential DEGs from GSE28571, GSE37745, GSE43580, and GSE50081, respectively (Figure [2](#F2){ref-type="fig"}, [Supplementary Table 1](#SD2){ref-type="supplementary-material"}--[4](#SD5){ref-type="supplementary-material"}). Removal of duplicate genes and expression values lacking specific gene symbols left 176 DEGs from GSE28571 ([Supplementary Table 5](#SD6){ref-type="supplementary-material"}), 153 from GSE37745 ([Supplementary Table 6](#SD7){ref-type="supplementary-material"}), 81 from GSE43580 ([Supplementary Table 7](#SD8){ref-type="supplementary-material"}) and 71 from GSE50081 ([Supplementary Table 8](#SD9){ref-type="supplementary-material"}).

![Potential DEGs between LADC and LSCC\
Heat maps for potential DEGs in GSE28571 (total n=243; LADC n=50; LSCC n=28) **(A)**, GSE37745 (total n=210; LADC n=106; LSCC n=66) **(B)**, GSE43580 (total n=118; LADC n=77; LSCC n=73) **(C)**, and GSE50081 (total n=101; LADC n=128; LSCC n=43) **(D).**](oncotarget-08-71759-g002){#F2}

Potential biomarkers for distinguishing between LADC and LSCC {#s2_3}
-------------------------------------------------------------

Based on expression fold changes between LADC and LSCC, we selected the top 10 downregulated and upregulated DEGs from GSE28571 (Table [1](#T1){ref-type="table"}), GSE37745 (Table [2](#T2){ref-type="table"}), GSE43580 (Table [3](#T3){ref-type="table"}), and GSE50081 (Table [4](#T4){ref-type="table"}). We identified four downregulated DEGs (desmoglein 3, DSG3; keratin 5, KRT5; keratin 6A, KRT6A; keratin 6B, KRT6B) (Figure [3](#F3){ref-type="fig"}) and four upregulated DEGs (NK2 homeobox 1, NKX2-1; surfactant associated 2, SFTA2; surfactant associated 3, SFTA3; transmembrane channel-like 5, TMC5) (Figure [4](#F4){ref-type="fig"}) that were present in all four datasets. We achieved similar results via an integrated analysis based on all four datasets together ([Supplementary Table 9](#SD10){ref-type="supplementary-material"}--[10](#SD11){ref-type="supplementary-material"}). We assessed these eight genes as potential biomarkers for discriminating LADC and LSCC.

###### Top 10 down- or upregulated DEGs between LADC and LSCC in lung cancer dataset, GSE28571

  Probe set ID   Gene symbol   Gene description                                             Gene feature     Fold change
  -------------- ------------- ------------------------------------------------------------ ---------------- -------------
  209125_at      KRT6A         keratin 6A                                                   downregulation   −176.148978
  206165_s\_at   CLCA2         chloride channel accessory 2                                 downregulation   −90.443266
  235075_at      DSG3          desmoglein 3                                                 downregulation   −88.129812
  201820_at      KRT5          keratin 5                                                    downregulation   −82.362516
  217272_s\_at   SERPINB13     serpin peptidase inhibitor, clade B (ovalbumin), member 13   downregulation   −64.457025
  213680_at      KRT6B         keratin 6B                                                   downregulation   −52.540652
  204455_at      DST           dystonin                                                     downregulation   −46.258579
  209863_s\_at   TP63          tumor protein p63                                            downregulation   −45.820729
  206032_at      DSC3          desmocollin 3                                                downregulation   −43.549951
  204855_at      SERPINB5      serpin peptidase inhibitor, clade B (ovalbumin), member 5    downregulation   −39.535047
  244056_at      SFTA2         surfactant associated 2                                      upregulation     31.032507
  228979_at      SFTA3         surfactant associated 3                                      upregulation     27.153369
  211024_s\_at   NKX2-1        NK2 homeobox 1                                               upregulation     15.422392
  219580_s\_at   TMC5          transmembrane channel-like 5                                 upregulation     11.725501
  229105_at      GPR39         G protein-coupled receptor 39                                upregulation     6.443132
  214033_at      ABCC6         ATP-binding cassette, sub-family C (CFTR/MRP), member 6      upregulation     6.288185
  212328_at      LIMCH1        LIM and calponin homology domains 1                          upregulation     6.28786
  225822_at      TMEM125       transmembrane protein 125                                    upregulation     5.919894
  230875_s\_at   ATP11A        ATPase, class VI, type 11A                                   upregulation     5.787312
  228806_at      RORC          RAR-related orphan receptor C                                upregulation     5.335111

###### Top 10 down- or upregulated DEGS between LADC and LSCC in lung cancer dataset, GSE37745

  Probe set ID   Gene symbol   Gene description                                             Gene feature     Fold change
  -------------- ------------- ------------------------------------------------------------ ---------------- -------------
  209125_at      KRT6A         keratin 6A                                                   downregulation   −140.927
  235075_at      DSG3          desmoglein 3                                                 downregulation   −86.646
  206165_s\_at   CLCA2         chloride channel accessory 2                                 downregulation   −84.9649
  201820_at      KRT5          keratin 5                                                    downregulation   −62.2157
  213680_at      KRT6B         keratin 6B                                                   downregulation   −53.2072
  206032_at      DSC3          desmocollin 3                                                downregulation   −47.29
  209863_s\_at   TP63          tumor protein p63                                            downregulation   −44.3825
  204455_at      DST           dystonin                                                     downregulation   −38.1615
  213796_at      SPRR1A        small proline-rich protein 1A                                downregulation   −36.8294
  217272_s\_at   SERPINB13     serpin peptidase inhibitor, clade B (ovalbumin), member 13   downregulation   −36.3898
  228979_at      SFTA3         surfactant associated 3                                      upregulation     33.59706
  244056_at      SFTA2         surfactant associated 2                                      upregulation     27.97213
  216623_x\_at   TOX3          TOX high mobility group box family member 3                  upregulation     21.41014
  206239_s\_at   SPINK1        serine peptidase inhibitor, Kazal type 1                     upregulation     17.47105
  211024_s\_at   NKX2-1        NK2 homeobox 1                                               upregulation     16.6846
  223806_s\_at   NAPSA         napsin A aspartic peptidase                                  upregulation     14.23227
  37004_at       SFTPB         surfactant protein B                                         upregulation     12.19793
  240304_s\_at   TMC5          transmembrane channel-like 5                                 upregulation     11.27782
  204424_s\_at   LMO3          LIM domain only 3 (rhombotin-like 2)                         upregulation     10.23422
  219612_s\_at   FGG           fibrinogen gamma chain                                       upregulation     9.826917

###### Top 10 down- or upregulated DEGs between LADC and LSCC in lung cancer dataset, GSE43580

  Probe set ID   Gene symbol   Gene description                                             Gene feature     Fold change
  -------------- ------------- ------------------------------------------------------------ ---------------- -------------
  209125_at      KRT6A         keratin 6A                                                   downregulation   −53.2466
  235075_at      DSG3          desmoglein 3                                                 downregulation   −45.44
  206165_s\_at   CLCA2         chloride channel accessory 2                                 downregulation   −38.0985
  209863_s\_at   TP63          tumor protein p63                                            downregulation   −28.6096
  213796_at      SPRR1A        small proline-rich protein 1A                                downregulation   −27.828
  201820_at      KRT5          keratin 5                                                    downregulation   −26.5195
  206032_at      DSC3          desmocollin 3                                                downregulation   −25.687
  213680_at      KRT6B         keratin 6B                                                   downregulation   −25.5837
  217272_s\_at   SERPINB13     serpin peptidase inhibitor, clade B (ovalbumin), member 13   downregulation   −22.7939
  209351_at      KRT14         keratin 14                                                   downregulation   −21.4751
  216623_x\_at   TOX3          TOX high mobility group box family member 3                  upregulation     12.48837
  228979_at      SFTA3         surfactant associated 3                                      upregulation     9.698342
  244056_at      SFTA2         surfactant associated 2                                      upregulation     9.34222
  220393_at      LGSN          lengsin, lens protein with glutamine synthetase domain       upregulation     7.272057
  223806_s\_at   NAPSA         napsin A aspartic peptidase                                  upregulation     6.387242
  211024_s\_at   NKX2-1        NK2 homeobox 1                                               upregulation     6.235382
  240304_s\_at   TMC5          transmembrane channel-like 5                                 upregulation     5.886752
  229030_at      CAPN8         calpain 8                                                    upregulation     5.558286
  209016_s\_at   KRT7          keratin 7                                                    upregulation     5.197863
  206239_s\_at   SPINK1        serine peptidase inhibitor, Kazal type 1                     upregulation     5.028636

###### Top 10 down- or upregulated DEGs between LADC and LSCC in lung cancer dataset, GSE50081

  Probe set ID   Gene symbol   Gene description                                               Gene feature     Fold change
  -------------- ------------- -------------------------------------------------------------- ---------------- -------------
  209125_at      KRT6A         keratin 6A                                                     downregulation   −57.006103
  213680_at      KRT6B         keratin 6B                                                     downregulation   −39.001783
  201820_at      KRT5          keratin 5                                                      downregulation   −37.082683
  207935_s\_at   KRT13         keratin 13                                                     downregulation   −23.955773
  210020_x\_at   CALML3        calmodulin-like 3                                              downregulation   −22.527441
  235075_at      DSG3          desmoglein 3                                                   downregulation   −21.167905
  213796_at      SPRR1A        small proline-rich protein 1A                                  downregulation   −20.461997
  221854_at      PKP1          plakophilin 1 (ectodermal dysplasia/skin fragility syndrome)   downregulation   −18.214428
  205157_s\_at   JUP           junction plakoglobin                                           downregulation   −17.594235
  209351_at      KRT14         keratin 14                                                     downregulation   −16.96603
  228979_at      SFTA3         surfactant associated 3                                        upregulation     13.36924
  244056_at      SFTA2         surfactant associated 2                                        upregulation     13.198138
  211024_s\_at   NKX2-1        NK2 homeobox 1                                                 upregulation     11.03073
  240304_s\_at   TMC5          transmembrane channel-like 5                                   upregulation     8.335526
  206239_s\_at   SPINK1        serine peptidase inhibitor, Kazal type 1                       upregulation     7.171856
  209016_s\_at   KRT7          keratin 7                                                      upregulation     6.780702
  204124_at      SLC34A2       solute carrier family 34 (sodium phosphate), member 2          upregulation     6.362828
  204437_s\_at   FOLR1         folate receptor 1 (adult)                                      upregulation     6.138674
  229177_at      C16orf89      chromosome 16 open reading frame 89                            upregulation     6.035951
  204424_s\_at   LMO3          LIM domain only 3 (rhombotin-like 2)                           upregulation     5.987309

![Venn diagram showing downregulated DEGs common to all four GEO datasets](oncotarget-08-71759-g003){#F3}

![Venn diagram showing upregulated DEGs common to all four GEO datasets](oncotarget-08-71759-g004){#F4}

Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic values of DSG3, KRT5, KRT6A, KRT6B, NKX2-1, SFTA2, SFTA3, and TMC5. The four downregulated DEGs had similar areas under the curve (AUC): 0.9188 for DSG3, 0.9386 for KRT5, 0.9333 for KRT6A, and 0.9229 for KRT6B (Figure [5A](#F5){ref-type="fig"}). The four upregulated DEGs also had similar AUCs: 0.8723 for NKX2-1, 0.8559 for SFTA2, 0.8108 for SFTA3, and 0.8442 for TMC5 (Figure [5B](#F5){ref-type="fig"}). AUC results showed that KRT5 had the highest diagnostic value for discriminating LADC and LSCC.

![ROC curves for downregulated **(A)** and upregulated DEGs **(B)** in distinguishing between LADC and LSCC. TPR: true positive rate; FPR: false positive rate; AUC: area under the curve.](oncotarget-08-71759-g005){#F5}

PrognoScan identified potential prognostic factors for LADC and LSCC patients {#s2_4}
-----------------------------------------------------------------------------

We assessed the prognostic values of the eight potential biomarkers using the bioinformatics analysis platform, PrognoScan. *P*\<0.05 was considered significant in Cox regression analyses. We found that high DSG3, KRT6A, or KRT6B levels (Table [5](#T5){ref-type="table"}), or low NKX2-1, SFTA3, or TMC5 levels (Table [6](#T6){ref-type="table"}), were associated with unfavorable prognosis in LADC patients. However, only low NKX2-1 expression was associated with unfavorable prognosis in LSCC patients (Table [6](#T6){ref-type="table"}). We speculated that DSG3, KRT6A, KRT6B, NKX2-1, SFTA3, and TMC5 might be LADC patient prognostic factors, and NKX2-1 might be an LSCC patient prognostic factor. Because each lung cancer microarray dataset in PrognoScan contained limited cases (Table [5](#T5){ref-type="table"}--[6](#T6){ref-type="table"}), we verified these findings using Kaplan-Meier Plotter.

###### DSG3, KRT5, KRT6A, and KRT6B prognostic values in LADC and LSCC as assessed by PrognoScan

  Gene symbol   LADC              LSCC                                                 
  ------------- ----------------- ------ ------------------- ---------- ---- ---- ---- --------
  **DSG3**      MICHIGAN-LC       86     2.54 (1.22-5.32)    0.013244   \-   \-   \-   \>0.05
  KRT5          \-                \-     \-                  \>0.05     \-   \-   \-   \>0.05
  **KRT6A**     jacob-00182-HLM   79     1.24 (1.06--1.45)   0.006974   \-   \-   \-   \>0.05
                jacob-00182-MSK   104    1.28 (1.06--1.53)   0.008562                  
                GSE31210          204    1.39 (1.18--1.63)   0.000083                  
  **KRT6B**     jacob-00182-MSK   104    1.26 (1.07--1.47)   0.005120   \-   \-   \-   \>0.05
                GSE31210          204    1.47 (1.23--1.75)   0.000017                  

###### NKX2-1, SFTA2, SFTA3, and TMC5 prognostic values in LADC and LSCC as assessed by PrognoScan

  Gene symbol   LADC                LSCC                                                                     
  ------------- ------------------- ------ ------------------- ---------- ---------- ---- ------------------ ----------
  **NKX2-1**    jacob-00182-CANDF   82     0.78 (0.64--0.96)   0.020132   GSE17710   56   0.71 (0.52-0.97)   0.029764
                jacob-00182-HLM     79     0.78 (0.63--0.97)   0.027745                                      
                MICHIGAN-LC         86     0.56 (0.36--0.87)   0.009902                                      
                GSE31210            204    0.62 (0.43--0.88)   0.008218                                      
                jacob-00182-UM      178    0.81 (0.68--0.97)   0.021112                                      
  SFTA2         \-                  \-     \-                  \>0.05     \-         \-   \-                 \-
  **SFTA3**     GSE13213            117    0.89 (0.79--1.00)   0.048445   \-         \-   \-                 \-
                GSE31210            204    0.62 (0.46--0.85)   0.003019                                      
  **TMC5**      jacob-00182-HLM     79     0.45 (0.24--0.84)   0.012012   \-         \-   \-                 \>0.05
                GSE31210            204    0.30 (0.13--0.68)   0.004014                                      

Kaplan-meier plotter verified five LADC prognostic factors {#s2_5}
----------------------------------------------------------

Using Kaplan-Meier Plotter, we verified that high KRT6A (Hazard ratio, HR=1.66; 95% confidence intervals, 95% CIs: 1.31--2.11; *P*=1.90E-05) or KRT6B (HR=1.76; 95% CIs: 1.39--2.22; *P*=1.90E-06) (Figure [6](#F6){ref-type="fig"}, Table [7](#T7){ref-type="table"}), or low NKX2-1 (HR=0.66; 95% CIs: 0.52--0.84; *P*=0.00051), SFTA3 (HR=0.55; 95% CIs: 0.43--0.70; *P*=1.20E-06), or TMC5 (HR=0.51; 95% CIs: 0.41--0.65; *P*=3.30E-08) (Figure [7](#F7){ref-type="fig"}, Table [7](#T7){ref-type="table"}) levels correlated with unfavorable prognosis in LADC patients. However, no DEGs correlated with LSCC patient prognosis (Table [7](#T7){ref-type="table"}). Unlike the scattered results obtained by PrognoScan, Kaplan-Meier Plotter gained the meta-analysis results and we therefore draw our conclusions based on the Kaplan-Meier Plotter findings.

![Kaplan-Meier survival curves for KRT6A and KRT6B expression in LADC patients](oncotarget-08-71759-g006){#F6}

###### Verification of potential prognostic indicators via Kaplan-Meier Plotter

  Gene symbol   LADC   LSCC                                                             
  ------------- ------ ----------------------- -------------- ----- ------------------- ------
  DSG3          673    1.09 (0.86-1.39)        0.48           271   0.86 (0.63--1.18)   0.35
  **KRT6A**     720    **1.66 (1.31--2.11)**   **1.90E-05**   524   0.99 (0.78--1.25)   0.92
  **KRT6B**     720    **1.76 (1.39--2.22)**   **1.90E-06**   524   0.94 (0.75--1.20)   0.63
  **NKX2-1**    720    **0.66 (0.52--0.84)**   **0.00051**    524   0.82 (0.65--1.04)   0.11
  **SFTA3**     673    **0.55 (0.43--0.70)**   **1.20E-06**   271   0.82 (0.60--1.11)   0.20
  **TMC5**      720    **0.51 (0.41--0.65)**   **3.30E-08**   524   1.02 (0.8--1.29)    0.88

![Kaplan-Meier survival curves for NKX2-1, SFTA3, and TMC5 expression in LADC patients](oncotarget-08-71759-g007){#F7}

DISCUSSION {#s3}
==========

In this study, we imported four GEO datasets into the GCBI comprehensive analysis platform to extract LADC and LSCC gene expression data. We identified DEGs between LADC and LSCC samples through differential expression analysis in GCBI, and found that DSG3, KRT5, KRT6A, KRT6B, NKX2-1, SFTA2, SFTA3, and TMC5 were potential biomarkers for distinguishing the two cancer types. According to ROC analyses, KRT5 had the highest diagnostic value for discriminating LADC and LSCC. Finally, using the survival analysis platforms, PrognoScan and Kaplan-Meier Plotter, we found that high KRT6A or KRT6B, or low NKX2-1, SFTA3, or TMC5 levels correlated with unfavorable prognoses in LADC patients.

Previous studies reported that DSG3 \[[@R18], [@R21], [@R22]\], KRT5 \[[@R23]\], KRT6A \[[@R24]\], and KRT6B \[[@R24]\] levels were higher in LSCC than in LADC, and that NKX2-1 \[[@R25]--[@R27]\], SFTA3 \[[@R21]\], and TMC5 \[[@R21]\] levels were higher in LADC than in LSCC, suggesting that these genes were biomarkers for differentiating between LSCC and LADC. In agreement with this, our results showed that DSG3, KRT5, KRT6A, and KRT6B were downregulated in LADC compared to LSCC, and that NKX2-1, SFTA3, and TMC5 were upregulated in LADC compared to LSCC. Our study also identified SFTA2 as a novel biomarker upregulated in LADC.

The potential biomarker, NKX2-1, binds DNA damage-binding protein 1 (DDB1) and degrades check-point kinase 1 (CHK1) to facilitate lung adenocarcinoma progression \[[@R28]\]. Through modulating IKKβ/NF-κB pathway activation, NKX2-1 also modulates lung adenocarcinoma by directly regulating p53 transcription \[[@R29]\]. However, the molecular mechanisms by which DSG3, KRT5, KRT6A, KRT6B, SFTA2, SFTA3, and TMC5 regulate NSCLC development remain unclear. DSG3 promotes epidermoid carcinoma progression by regulating activation of protein kinase C-dependent Ezrin and activator protein 1 \[[@R30]\]. KRT5 combines with transforming growth factor beta receptor 3 (TGFBR3) and transcription factor JunD to promote breast cancer cell growth \[[@R31]\]. KRT6B interacts with notch1 to promote renal carcinoma development \[[@R32]\]. Studies to elucidate the mechanisms of action of these biomarkers in NSCLC development and progression are warranted.

Lu C, *et al.* \[[@R33]\] and Tian \[[@R34]\] also extracted gene expression data from GEO profiles to identify DEGs between LADC and LSCC. Based on the GSE6044 and GSE50081 datasets, these groups identified 19 and 33 DEGs, respectively, that might discriminate between LADC and LSCC. However, these genes were not identified based on expression fold changes between LADC and LSCC. Fold change is important for detecting DEGs \[[@R35]--[@R37]\] and guiding further research \[[@R38], [@R39]\], and our eight potential biomarkers for differentiating between LADC and LSCC were identified based on this measurement type in the GSE28571, GSE37745, GSE43580, and GSE50081 datasets. Consequently, the biomarkers reported here differ from those identified in previous studies \[[@R33], [@R34]\]. This indicates that different gene expression dataset screening methods may produce different results and the differences of molecule expression between LADC and LSCC may be far more complicated than we thought.

Previous studies have identified prognostic biomarkers in patients with LADC \[[@R10], [@R40]--[@R44]\] or LSCC \[[@R45]--[@R49]\]. While we did not identify any LSCC prognostic indictors, we found that high KRT6A or KRT6B levels, or low NKX2-1, SFTA3, or TMC5 levels correlated with an unfavorable prognosis in LADC patients. Of these prognostic factors, only NKX2-1, thought to be a tumor suppressor \[[@R50]\], was previously associated with LADC prognosis \[[@R26], [@R51]\]. The prognostic values of KRT6A, KRT6B, SFTA3, and TMC5 in LADC are reported here for the first time. Both KRT6A and KRT6B are type II cytokeratins and keratin 6 isoforms \[[@R52], [@R53]\]. KRT6A and KRT6B are associated with pachyonychia congenita \[[@R54], [@R55]\], as well as renal carcinoma \[[@R32]\] and breast cancer \[[@R56]\] progression. SFTA3 is an immunoregulatory protein that protects lung tissue during inflammation and is likely a lung surfactant protein family member \[[@R57]\]. SFTA3 is also downregulated in anaplastic thyroid carcinoma compared with normal thyroid tissue \[[@R58]\]. TMC5 is a transmembrane protein with at least eight membrane-spanning domains that belongs to a novel group of transporters, ion channels, or modifiers of such \[[@R59]\]. TMC5 is upregulated in chromophobe renal cell carcinoma \[[@R60]\] and intrahepatic cholangiocarcinoma \[[@R61]\].

In conclusion, we identified DSG3, KRT5, KRT6A, KRT6B, NKX2-1, SFTA2, SFTA3, and TMC5 as potential biomarkers for distinguishing between LADC and LSCC. Additionally, high KRT6A or KRT6B levels, or low NKX2-1, SFTA3, or TMC5 levels correlated with unfavorable LDAC patient prognosis. Further studies are required to verify our findings in additional patient samples, and to elucidate the mechanisms of action of these potential biomarkers in NSCLC.

MATERIALS AND METHODS {#s4}
=====================

Gene expression omnibus datasets {#s4_1}
--------------------------------

The Gene Expression Omnibus (GEO) (<https://www.ncbi.nlm.nih.gov/gds>) is a public repository at the National Center of Biotechnology Information for storing high throughput gene expression datasets. We screened potential GEO datasets according to the following inclusion criteria: 1) *Homo sapiens* NSCLC specimens classified as LADC or LSCC; 2) expression profiling by array; 3) performed on the GPL570 platform (\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array); and 4) ≥100 samples. Datasets with specimens from other organisms, expression profiling by RT-PCR (or genome variation profiling by SNP array/SNP genotyping by SNP array), analyses on platforms other than GPL570, or sample size \<100 were excluded.

We used the search terms, "((lung cancer \[Title\]) AND GPL570 \[Related Series\]) AND *Homo sapiens* \[Organism\] AND (squamous cell carcinoma \[Description\] OR adenocarcinoma \[Description\])," to identify potential datasets within GEO. Screening using the aforementioned inclusion criteria identified four datasets (GSE28571, GSE37745, GSE43580, and GSE50081) for use in analyses of DEGs between LADC and LSCC. These datasets contained 361 LADC (50 in GSE28571, 106 in GSE37745, 77 in GSE43580, and 128 in GS50081) and 210 LSCC (28 in GSE28571, 66 in GSE37745, 73 in GSE43580, and 43 in GSE50081) fresh-frozen specimens ([Tables S11](#SD12){ref-type="supplementary-material"}--[S14](#SD15){ref-type="supplementary-material"}).

Gene-cloud of biotechnology information {#s4_2}
---------------------------------------

Gene-Cloud of Biotechnology Information (GCBI; <https://www.gcbi.com.cn/gclib/html/index>), is an online comprehensive bioinformatics analysis platform that can systematically analyze GEO dataset-derived gene expression information \[[@R62]\]. After flagged data normalization, filtering, and quality control, we identified genes differentially expressed by \>5 fold between LADC and LSCC, with the cutoff values *P*\<0.05 and Q\<0.05 using GCBI.

Prognoscan {#s4_3}
----------

The PrognoScan (<http://www.prognoscan.org/>) online database provides a powerful platform for exploring therapeutic targets, tumor markers, and prognostic factors in cancer patients \[[@R63]\], and contains cancer microarray datasets with corresponding clinical data. PrognoScan automatically calculates HRs, 95% CIs, and Cox *P*-values according to a given gene\'s mRNA level (high or low).

Kaplan-meier plotter {#s4_4}
--------------------

Kaplan-Meier Plotter (<http://kmplot.com/analysis/>) is an online database of published microarray datasets for four cancer types (breast, ovarian, lung, and gastric cancer), and includes clinical data and gene expression information for 2,437 lung cancer patients \[[@R64]\]. Kaplan-Meier Plotter is useful for assessing new biomarkers related to lung cancer patient survival.

Receiver operating characteristic curve analyses {#s4_5}
------------------------------------------------

Receiver operating characteristic (ROC) curves were constructed to compare biomarker diagnostic values. Curves are created by plotting true positive rates (TPR, sensitivity) against false positive rates (FPR, 1-specificity). The area under the curve (AUC) is used to determine diagnostic accuracy. An AUC value close to 1.0 indicates high accuracy \[[@R65]\].
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